482 studies found for:    "Squamous cell carcinoma of the head and neck"
Show Display Options
RSS Create an RSS feed from your search for:
"Squamous cell carcinoma of the head and neck"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Patients Who Are Resistant or Ineligible/Intolerant to Platinum-based Chemotherapy.;   Recurrent Head and Neck Squamous Cell Carcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Drug: BYL719+cetuximab;   Biological: cetuximab
2 Completed A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
3 Terminated EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
4 Completed
Has Results
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab;   Drug: EMD 1201081
5 Active, not recruiting E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Condition: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: E7050;   Drug: Cetuximab
6 Unknown  Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Radiation: 3 Dimensional Radiation Therapy;   Radiation: Intensity Modulated Radiation Therapy
7 Recruiting A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Afatinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cisplatin;   Radiation: Intensity Modulated Radiation Therapy
8 Recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
9 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
10 Unknown  Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region
Intervention: Other: Integrated FDG PET/CT
11 Recruiting Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: AFATINIB;   Drug: Placebo of  AFATINIB
12 Active, not recruiting IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Carcinoma
Interventions: Radiation: Accl. RT;   Radiation: Accl. radiotherapy + Nimorazole
13 Active, not recruiting Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
14 Recruiting Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Plasma samples
15 Unknown  Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Bevacizumab;   Drug: erlotinib;   Drug: Sulindac
16 Not yet recruiting Window Trial 5-aza in HNSCC, T-tare
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: 5-Azacitadine
17 Completed Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Conditions: Advanced Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   SSCHN
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: 5-Fluorouracil
18 Unknown  Erlotinib, Radiation Therapy and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Erlotinib clorhidrate;   Drug: Cisplatin;   Procedure: Radiation therapy
19 Terminated Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus;   Drug: cisplatin;   Drug: cetuximab
20 Unknown  MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Biological: MAGE-A3;   Biological: HPV-16  vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years